List of Excipients in Branded Drug RETACRIT

Retacrit Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Retacrit is epoetin alfa-epbx, a recombinant erythropoietin biosimilar developed by Hospira and marketed by Pfizer. Its formulation uses a conventional protein-stabilization system based on polysorbate 20, phosphate buffer, sodium chloride, glycine, and water for injection. Multidose presentations also contain benzyl alcohol. The main commercial opportunity is not a new active ingredient. It is differentiated delivery, preservative-free multidose use, supply reliability, and lower-cost administration across oncology, dialysis, and selected non-dialysis settings.

Retacrit was approved by the FDA in 2018 under the 351(k) biosimilar pathway. It is not designated interchangeable by the FDA, and its commercial position depends heavily on contracting, payer controls, hospital formularies, and acquisition cost rather than on exclusivity from a novel excipient platform (FDA, 2018a; FDA, 2024a).

What excipients are used in Retacrit?

Retacrit contains a protein-stabilizing and isotonic formulation designed for subcutaneous or intravenous injection.

Formulation component	Functional role
Epoetin alfa-epbx	Active recombinant glycoprotein
Polysorbate 20	Surfactant that limits adsorption and interface-induced aggregation
Sodium chloride	Tonicity adjustment
Sodium phosphate monobasic monohydrate	Buffer component
Sodium phosphate dibasic anhydrous	Buffer component
Glycine	Stabilizer and tonicity contributor
Water for injection	Vehicle
Benzyl alcohol	Preservative in multidose presentations

The FDA prescribing information identifies polysorbate 20, sodium chloride, phosphate salts, glycine, and water for injection as inactive components. Benzyl alcohol is present in multidose vials and creates a separate use limitation for certain pediatric and neonatal populations (Pfizer, 2024).

The excipient strategy is conservative. It uses common parenteral ingredients with established regulatory histories rather than a novel stabilizer, amino-acid system, sugar platform, or proprietary surfactant. That approach reduces formulation and regulatory risk but leaves limited room for composition-based differentiation.

Why does Retacrit use polysorbate 20 and glycine?

Polysorbate 20 protects epoetin alfa-epbx against surface adsorption and agitation-related instability. Recombinant proteins can lose activity or form aggregates when exposed to vial walls, air-liquid interfaces, silicone oil, shipping vibration, or repeated handling. Surfactant selection affects aggregation, oxidation, subvisible particles, and container compatibility.

Glycine contributes to protein stabilization and tonicity. Its use with phosphate buffer and sodium chloride is consistent with established biologic injectable formulation practice. The combination provides a relatively familiar excipient profile for FDA review and hospital pharmacy handling.

The commercial tradeoff is that polysorbate-containing formulations remain exposed to known development issues:

• Oxidative degradation of the surfactant and formation of degradation products.
• Potential interaction with container closure systems.
• Particle generation during storage or agitation.
• Compatibility constraints with prefilled syringes and silicone oil.
• Limited flexibility for high-concentration or long-term room-temperature products.

Retacrit’s excipient system therefore supports biosimilar comparability, but it does not create a strong standalone formulation moat.

What are the Retacrit dosage forms and excipient implications?

Retacrit is supplied in single-dose and multidose vial configurations. Presentation-specific excipient differences are commercially important because they determine use in hospitals, clinics, dialysis centers, and home administration.

Single-dose vials

Single-dose vials avoid preservative exposure and are better suited to patients for whom benzyl alcohol is undesirable. They generate more packaging waste and may have a higher per-unit acquisition cost because unused contents generally cannot be carried over for another patient.

Single-dose presentations are practical for:

• Oncology clinics administering patient-specific doses.
• Pediatric use where preservative avoidance is preferred.
• Hospital pharmacies operating under strict single-use policies.
• Settings with low predictable daily volume.

Multidose vials

Multidose vials improve dose flexibility and can reduce product waste where repeated access is operationally controlled. Benzyl alcohol supports multidose use but limits the product’s positioning in neonates and requires careful review for pediatric and pregnancy-related use.

Multidose economics are strongest where:

• Several patients receive epoetin on the same day.
• The institution has controlled aseptic compounding and administration processes.
• Dose variability makes fixed single-dose presentations inefficient.
• Inventory turnover is high enough to avoid discard.

The tradeoff is clinical and regulatory: multidose efficiency must be balanced against preservative exposure, contamination controls, beyond-use handling, and patient population restrictions.

What commercial opportunities exist for Retacrit excipient innovation?

The strongest opportunities are delivery and use-system improvements rather than a simple substitution of one conventional excipient for another.

Preservative-free multidose technology

A preservative-free multidose system could address a clear market tension: institutions want multidose efficiency, while clinicians often prefer preservative-free products for vulnerable populations. Commercially relevant technologies could include:

• Sterile barrier systems.
• One-way valve closures.
• Closed-vial access devices.
• Antimicrobial container technologies.
• Integrated dose-management systems.

Any such system would require extensive container-closure integrity, microbial ingress, extractables and leachables, in-use stability, and multidose-use validation. The technology could support composition, container, device, or method-of-use patent claims.

Prefilled syringes and low-waste administration

A prefilled syringe could reduce preparation time, dosing errors, and vial waste. The major formulation challenges are compatibility with syringe materials, silicone oil, tungsten residues, plunger elastomers, and mechanical stress during shipping.

For epoetin products, prefilled syringes could be valuable in:

• Outpatient oncology.
• Home administration.
• Specialty pharmacy distribution.
• Dialysis-related anemia management.
• Smaller clinics with limited pharmacy infrastructure.

A prefilled product would need to compete against the lower acquisition cost of vial-based Retacrit and against existing provider workflows.

Higher-concentration formulations

Higher-concentration epoetin formulations could reduce injection volume and improve usability. The development risks include increased protein concentration, aggregation, viscosity, particle formation, and syringeability. Higher concentration also may change the exposure profile of polysorbate 20 and increase sensitivity to container surfaces.

A commercially attractive product would need to demonstrate a practical benefit, such as:

• Lower injection volume.
• Fewer injections.
• Better compatibility with autoinjectors.
• Easier home use.
• Reduced storage and shipping burden.

A concentration change alone would not guarantee market adoption. Payers and providers may treat the product as interchangeable for reimbursement purposes unless the device or clinical workflow produces a measurable economic benefit.

Room-temperature stability

Retacrit labeling requires refrigerated storage. A formulation that tolerates controlled room-temperature exposure would have value in home care, specialty pharmacy, international distribution, and emergency inventory planning.

Potential approaches include:

• Alternative surfactant systems.
• Sugar-based stabilization.
• Amino-acid combinations.
• Lyophilization.
• Improved primary packaging.
• Optimized freeze-thaw and agitation resistance.

The commercial case depends on the duration of permitted room-temperature storage and whether the benefit reduces cold-chain cost or product waste. A modest stability improvement may have limited value if the product still requires refrigerated distribution.

Alternative surfactant systems

Replacing polysorbate 20 with polysorbate 80, poloxamer, or another protein-compatible surfactant may reduce specific degradation pathways. However, a new surfactant changes the biosimilar comparability package and requires fresh evaluation of:

• Protein aggregation.
• Higher-order structure.
• Glycosylation comparability.
• Potency.
• Immunogenicity risk.
• Subvisible particles.
• Leachables and degradation products.

For an established biosimilar, the regulatory and manufacturing burden may exceed the commercial benefit unless the change enables a new presentation or a major shelf-life improvement.

How does Retacrit’s excipient strategy affect biosimilar regulation?

A biosimilar does not always have to use the same inactive ingredients as its reference product. The FDA evaluates whether differences affect safety, purity, potency, or immunogenicity. For a protein injectable, excipient changes receive close scrutiny because they can alter aggregation, degradation, administration tolerability, and immune response (FDA, 2015).

A developer pursuing a Retacrit competitor or reformulated epoetin product would need to establish:

1. Analytical similarity of the active protein.
2. Comparable higher-order structure and glycosylation.
3. Comparable potency and receptor activity.
4. Comparable impurity and aggregate profiles.
5. Stability under intended storage conditions.
6. Container and device compatibility.
7. Acceptable immunogenicity risk.
8. Consistent manufacturing performance.

A novel excipient can create differentiation, but it also raises the cost of the comparability and clinical-development package. The safest commercial path is usually an incremental formulation change with a direct administration or supply-chain benefit.

What is the FDA regulatory status and exclusivity position of Retacrit?

Retacrit is a licensed biosimilar biologic, not a conventional small-molecule generic. The FDA approved epoetin alfa-epbx for indications including anemia associated with chronic kidney disease, chemotherapy, zidovudine treatment in HIV infection, and reduction of allogeneic red blood cell transfusion in selected surgical patients (FDA, 2018a).

Regulatory issue	Retacrit position
Active ingredient	Epoetin alfa-epbx
Reference products	Epogen and Procrit
FDA pathway	Section 351(k) biosimilar pathway
Approval date	May 15, 2018
Interchangeability	No FDA interchangeable designation identified
Orange Book listing	No, because Retacrit is a biologic
Relevant FDA database	Purple Book
Pediatric use	Benzyl alcohol limits multidose positioning in vulnerable populations
Main market access drivers	Contracting, formulary placement, payer policy, acquisition cost

Biologic exclusivity and patent rights are separate. Retacrit’s approval did not create a long-term market monopoly comparable to a new molecular entity. Competition is governed by reference-product patent settlements, biosimilar approvals, manufacturing capacity, reimbursement, and contracting.

What patent and intellectual-property barriers affect Retacrit excipient opportunities?

The principal intellectual-property risks are likely to arise from formulation, container, device, manufacturing, and use claims rather than from the basic use of common excipients.

Potential claim categories include:

• Epoetin formulations containing defined surfactant concentrations.
• Stable protein compositions with phosphate and amino-acid buffers.
• Lyophilized epoetin dosage forms.
• Prefilled syringe systems.
• Multidose containers with preservative-free access technology.
• Methods for reducing aggregation or injection-site reactions.
• Manufacturing processes that control glycosylation or impurity levels.
• Combination packaging and administration devices.

Common excipients such as sodium chloride, glycine, phosphate salts, and polysorbate 20 are unlikely to provide broad exclusivity by themselves. Patent value would depend on narrow concentration ranges, specific stability results, defined container systems, or a demonstrated administration advantage.

Because Retacrit is a biosimilar, a new excipient strategy may be commercialized through a separate product, a device-linked presentation, or a reformulated biologic license supplement. Patent protection should be paired with regulatory exclusivity, manufacturing know-how, and supply agreements. Formulation patents without manufacturing control may be easier to design around.

Which companies compete with Retacrit?

Retacrit competes with the reference products Epogen and Procrit, other epoetin products in international markets, and alternative erythropoiesis-stimulating agents.

Product	Active substance	Commercial relevance
Retacrit	Epoetin alfa-epbx	U.S. biosimilar marketed by Pfizer
Epogen	Epoetin alfa	Amgen reference product
Procrit	Epoetin alfa	Johnson & Johnson reference brand, historically marketed through Janssen
Aranesp	Darbepoetin alfa	Longer-acting ESA competitor
Mircera	Methoxy polyethylene glycol-epoetin beta	Long-acting ESA, marketed by Roche in applicable markets

Retacrit’s direct competitive advantage is typically price and contracting. Aranesp and Mircera compete through dosing frequency and clinical workflow rather than excipient composition. A new Retacrit formulation must therefore produce a measurable operational benefit to overcome established purchasing arrangements.

What generic launch and biosimilar entry risks exist for Retacrit?

The main entry risks are commercial rather than conventional generic substitution risks.

A competing epoetin biosimilar could enter with:

• Lower acquisition cost.
• A contract tied to dialysis or oncology networks.
• A prefilled syringe.
• A higher-concentration dose.
• A longer in-use period.
• A preservative-free multidose presentation.
• More flexible cold-chain handling.

The absence of automatic interchangeability can slow pharmacy-level substitution. Hospitals and clinics may still switch products through formulary decisions, tenders, and group purchasing contracts. For epoetin, purchasing decisions are especially sensitive to reimbursement spread, inventory reliability, and dose-management systems.

How strong is the Retacrit formulation estate?

Retacrit has a commercially practical but not obviously differentiated excipient platform. Its strengths are regulatory familiarity, manufacturing feasibility, and compatibility with established parenteral biologic practice. Its weaknesses are limited formulation exclusivity, refrigerated storage, preservative-related restrictions in multidose vials, and the absence of an FDA interchangeable designation.

The most defensible commercial extensions would combine:

• A differentiated device.
• A protected container-closure system.
• Improved stability.
• Lower administration burden.
• A validated preservative-free multidose design.
• Manufacturing know-how that is difficult to reproduce.

A copycat excipient composition would offer weak protection. A product that links formulation performance to a device, use method, and measurable economic benefit would have a stronger competitive position.

Key Takeaways

• Retacrit is epoetin alfa-epbx, a Pfizer-marketed biosimilar approved in 2018.
• Its core excipients are polysorbate 20, phosphate salts, sodium chloride, glycine, and water for injection.
• Multidose presentations contain benzyl alcohol, creating pediatric and vulnerable-population restrictions.
• The current formulation is conventional and regulatory-efficient but offers limited standalone formulation differentiation.
• The strongest commercial opportunities are preservative-free multidose delivery, prefilled syringes, higher concentration, reduced waste, and improved room-temperature stability.
• Retacrit is regulated as a biologic and is not listed in the Orange Book. The Purple Book and biologic licensing framework are more relevant.
• Competition comes from Epogen, Procrit, darbepoetin alfa, methoxy polyethylene glycol-epoetin beta, and potential future epoetin biosimilars.
• Patent value is more likely to reside in formulation ranges, containers, devices, manufacturing processes, and use methods than in common excipients alone.
• Commercial success depends on contracting, reimbursement, supply reliability, and workflow savings.

FAQs

Can Retacrit be reformulated without changing the active protein?

Yes. A reformulation may change inactive ingredients or presentation, but the sponsor must demonstrate that the change does not adversely affect product quality, potency, safety, purity, or immunogenicity.

Does benzyl alcohol make Retacrit unsuitable for all pediatric patients?

No. The concern is presentation-specific and population-specific. Multidose vials containing benzyl alcohol require particular caution, while preservative-free single-dose presentations may be more suitable when clinically appropriate.

Could a preservative-free Retacrit multidose vial command a premium?

Potentially. The premium would depend on reduced waste, broader patient eligibility, lower administration burden, and the ability to preserve multidose economics without increasing contamination risk.

Does Retacrit have an Orange Book patent listing?

No. Retacrit is a biologic, so its regulatory and patent framework is not the same as that for an FDA-approved small-molecule drug listed in the Orange Book. The Purple Book identifies licensed biological products and biosimilar relationships.

Is Retacrit automatically substitutable at the pharmacy?

No. Retacrit does not have an FDA interchangeable designation identified in the cited FDA records. Substitution and switching can still occur through institutional formularies, payer policies, contracts, and prescriber decisions.

References

1. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product

2. U.S. Food and Drug Administration. (2018a). FDA approves epoetin alfa-epbx for treatment of anemia. https://www.fda.gov/news-events/press-announcements/fda-approves-epoetin-alfa-epbx-treatment-anemia

3. U.S. Food and Drug Administration. (2024a). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

4. Pfizer Inc. (2024). Retacrit (epoetin alfa-epbx) injection: Prescribing information. https://labeling.pfizer.com/ShowLabeling.aspx?id=10738

5. U.S. Food and Drug Administration. (2024b). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/therapeutic-biologics-applications-blood/biosimilars-and-interchangeable-biosimilars